Top

Published in:

23-02-2024 | Ovarian Cancer | Gynecologic Oncology

Impact of Ovarian Cancer Surgery Volume on Overall and Progression-Free Survival: A Population-Based Retrospective National French Study

Authors: Pauline Prost, MD, Martha Duraes, MD, Vera Georgescu, PhD, Lucie Rebel, MD, Grégoire Mercier, MD, Gauthier Rathat, MD

Published in: Annals of Surgical Oncology | Issue 5/2024

Abstract

Background

Data are limited on the relationship between ovarian cancer surgery volume and outcomes in France.

Methods

For this retrospective, population-based study, patients with ovarian cancer that was diagnosed between January 1, 2012 and December 31, 2016 were identified from the French National Health Data System (SNDS). Hospitals were classified in function of their ovarian cancer surgery volume. Patient, tumor, hospital, and hospital stay characteristics also were evaluated. The hospital procedure volume effect on 5-year overall survival (OS) and recurrence-free survival (RFS) was determined with Cox-proportional hazards models.

Results

This study included 8429 patients and 53.4% underwent cytoreductive surgery in hospitals with procedure volume < 20 cases/year. The 5-year OS rates were 63% and 60% in hospitals with procedure volume ≥ 20 and < 20 cases/year (p = 0.02). In multivariate analysis, OS and RFS were significantly increased when surgery was performed in hospitals doing ≥ 20 surgeries/year (vs. < 20) (hazard ratio HR = 1.18, 95% CI = 1.08–1.29 and HR = 1.10, 95% CI = 1.03–1.17). In the volume subgroup analysis, a difference was observed mainly between hospitals with < 10 surgeries/year and the other hospitals (HR = 1.27, 95% CI = 1.14–1.41 and HR = 1.14, 95% CI = 1.05–1.23). The patients’ age and comorbidities, tumor stage, and hospital stay (duration, first cytoreduction surgery) were associated with OS.

Conclusions

Ovarian cancer surgery volume ≥ 20 cases/year was significantly associated with improved OS and RFS but only with a limited clinical benefit. The biggest differences in OS and RFS were observed between hospitals with procedure volume < 10 cases/year and all the other hospitals.

Available only for authorised users

Global Cancer Observatory: Cancer today. [GLOBOCAN web site]. 2020. Available at https://gco.iarc.fr/today. Accessed 1 Aug 2023.

Chang SJ, Bristow RE. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining ‘optimal’ residual disease. Gynecol Oncol. 2012;125(2):483–92. https://doi.org/10.1016/j.ygyno.2012.02.024.CrossRefPubMed

Chang SJ, Bristow RE, Chi DS, et al. Role of aggressive surgical cytoreduction in advanced ovarian cancer. J Gynecol Oncol. 2015;26(4):336–42. https://doi.org/10.3802/jgo.2015.26.4.336.CrossRefPubMedPubMedCentral

Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114(1):26–31. https://doi.org/10.1016/j.ygyno.2009.03.018.CrossRefPubMed

Bristow RE, Palis BE, Chi DS, et al. The national cancer database report on advanced-stage epithelial ovarian cancer: Impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol. 2010;118(3):262–7. https://doi.org/10.1016/j.ygyno.2010.05.025.CrossRefPubMed

Schrag D, Earle C, Xu F, et al. Associations between hospital and surgeon procedure volumes and patient outcomes after Ovarian cancer resection. JNCI J Natl Cancer Inst. 2006;98(3):163–71. https://doi.org/10.1093/jnci/djj018.CrossRefPubMed

Cliby WA, Powell MA, Al-Hammadi N, et al. Ovarian cancer in the United States: contemporary patterns of care associated with improved survival. Gynecol Oncol. 2015;136(1):11–7. https://doi.org/10.1016/j.ygyno.2014.10.023.CrossRefPubMed

Harter P, Muallem ZM, Buhrmann C, et al. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol. 2011;121(3):615–9. https://doi.org/10.1016/j.ygyno.2011.02.014.CrossRefPubMed

Querleu D, Planchamp F, Chiva L, et al. European society of gynaecologic oncology quality indicators for advanced ovarian cancer surgery. Int J Gynecol Cancer. 2016;26(7):1354–63. https://doi.org/10.1097/IGC.0000000000000767.CrossRefPubMed

10.

Institut National du Cancer. Thésaurus - Conduites à tenir initiales devant des patientes atteintes d'un cancer épithélial de l'ovaire. 2019. Available at https://www.e-cancer.fr. Accessed 1 Aug 2023.

11.

Legifrance. Arrêté du 26 avril 2022 portant modification de l’arrêté du 29 mars 2007 fixant les seuils d’activité minimale annuelle applicables à l’activité de soins de traitement du cancer. 2022. Available at https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000045668843. Accessed 4 Sept 2023.

12.

Meurette J, Daraï E, Tajahmady A, et al. Arguments for centralization of surgical treatment of ovarian cancer in France based on morbidity and mortality data. Bull Cancer. 2023;S0007–4551(23):00043–7. https://doi.org/10.1016/j.bulcan.2022.12.016.CrossRef

13.

Querleu D, Meurette J, Daraï E, et al. La chirurgie des cancers de l’ovaire: Évolution des pratiques en France. Bull Cancer. 2016;103(11):935–40. https://doi.org/10.1016/j.bulcan.2016.09.013.CrossRefPubMed

14.

Martinez A, Gertych W, Pomel C, et al. Adherence to French and ESGO quality indicators in ovarian cancer surgery: an Ad-Hoc analysis from the prospective multicentric CURSOC study. Cancers. 2021;13(7):1593. https://doi.org/10.3390/cancers13071593.CrossRef

15.

Tuppin P, Rudant J, Constantinou P, et al. Value of a national administrative database to guide public decisions: From the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Revue d’Épidémiologie et de Santé Publique. 2017;65:S149–67. https://doi.org/10.1016/j.respe.2017.05.004.CrossRefPubMed

16.

Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83. https://doi.org/10.1016/0021-9681(87)90171-8.CrossRefPubMed

17.

Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9. https://doi.org/10.1016/0895-4356(92)90133-8.CrossRefPubMed

18.

Gerestein CG, Damhuis RAM, de Vries M, et al. Causes of postoperative mortality after surgery for ovarian cancer. Eur J Cancer. 2009;45(16):2799–803. https://doi.org/10.1016/j.ejca.2009.06.004.CrossRefPubMed

19.

Ioka A, Tsukuma H, Ajiki W, et al. Influence of hospital procedure volume on ovarian cancer survival in Japan, a country with low incidence of ovarian cancer. Cancer Sci. 2004;95(3):233–7. https://doi.org/10.1111/j.1349-7006.2004.tb02208.x.CrossRefPubMed

20.

Sinno AK, Li X, Thompson RE, et al. Trends and factors associated with radical cytoreductive surgery in the United States: a case for centralized care. Gynecol Oncol. 2017;145(3):493–9. https://doi.org/10.1016/j.ygyno.2017.03.020.CrossRefPubMedPubMedCentral

21.

Dahm-Kähler P, Palmqvist C, Staf C, et al. Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival—a population-based cohort study. Gynecol Oncol. 2016;142(2):211–6. https://doi.org/10.1016/j.ygyno.2016.05.025.CrossRefPubMed

22.

Huguet M, Perrier L, Bally O, et al. Being treated in higher volume hospitals leads to longer progression-free survival for epithelial ovarian carcinoma patients in the Rhone-Alpes region of France. BMC Health Serv Res. 2018;18:23. https://doi.org/10.1186/s12913-017-2802-2.CrossRef

23.

Bristow RE, Chang J, Ziogas A, et al. High-volume ovarian cancer care: Survival impact and disparities in access for advanced-stage disease. Gynecol Oncol. 2014;132(2):403–10. https://doi.org/10.1016/j.ygyno.2013.12.017.CrossRefPubMed

24.

Bristow RE, Zahurak ML, Diaz-Montes TP, et al. Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes. Gynecol Oncol. 2009;115(3):334–8. https://doi.org/10.1016/j.ygyno.2009.08.025.CrossRefPubMed

25.

Mercado C, Zingmond D, Karlan BY, et al. Quality of care in advanced ovarian cancer: the importance of provider specialty. Gynecol Oncol. 2010;117(1):18–22. https://doi.org/10.1016/j.ygyno.2009.12.033.CrossRefPubMed

26.

Algera MD, Morton R, Sundar SS, et al. Exploring international differences in ovarian cancer care: a survey report on global patterns of care, current practices, and barriers. Int J Gynecol Cancer. 2023. https://doi.org/10.1136/ijgc-2023-004563.CrossRefPubMedPubMedCentral

27.

Norell CH, Butler J, Farrell R, et al. Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care. Int J Gynecol Cancer. 2020;30(11):1748–56. https://doi.org/10.1136/ijgc-2020-001403.CrossRefPubMedPubMedCentral

28.

Jochum F, Hamy AS, Gaillard T, et al. Impact of the area of residence of ovarian cancer patients on overall survival. Cancers. 2022;14(23):5987. https://doi.org/10.3390/cancers14235987.CrossRefPubMedPubMedCentral

29.

Gac MM, Loaec C, Silve J, et al. Quality of advanced ovarian cancer surgery: a French assessment of ESGO quality indicators. Eur J Surg Oncol. 2021;47(2):360–6. https://doi.org/10.1016/j.ejso.2020.08.003.CrossRefPubMed

30.

Paulsen T, Szczesny W, Kærn J, et al. Improved 8-year survival for patients with stage IIIC ovarian cancer operated on at teaching hospitals: Population-based study in Norway 2002. Clin Ovarian Gynecol Cancer. 2012;5(2):60–6. https://doi.org/10.1016/j.cogc.2012.12.002.CrossRef

Title: Impact of Ovarian Cancer Surgery Volume on Overall and Progression-Free Survival: A Population-Based Retrospective National French Study
Authors: Pauline Prost, MD
Martha Duraes, MD
Vera Georgescu, PhD
Lucie Rebel, MD
Grégoire Mercier, MD
Gauthier Rathat, MD
Publication date: 23-02-2024
Publisher: Springer International Publishing
Keywords: Ovarian Cancer
Ovarian Cancer
Cytostatic Therapy
Published in: Annals of Surgical Oncology / Issue 5/2024
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-024-15050-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Impact of Ovarian Cancer Surgery Volume on Overall and Progression-Free Survival: A Population-Based Retrospective National French Study

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2024

At the Speed of SOUND: The Pace of Change for Axillary Management in Breast Cancer

ASO Visual Abstract: Absence of Hypercoagulation Status After Neoadjuvant Treatment is Associated with Favorable Prognosis in Patients Undergoing Subtotal Esophagectomy for Esophageal Squamous Cell Carcinoma

Intratumoral Heterogeneity, Chemoresistance and Lymph Node Landing Zone Prognosis in Testicular Tumors Based on Histopathological Characteristics

Laparoscopic Portal Vein Ligation and Embolization During First-Stage Hepatectomy for Initially Unresectable Colorectal Liver Metastases

Neoadjuvant Chemotherapy is Associated with Increased Risk of Postoperative DVT After Distal Pancreatectomy for Pancreatic Adenocarcinoma: a NSQIP Analysis

ASO Author Reflections: Feasibility of Indocyanine Green Fluorescence Technique in Robotic Duodenum-Preserving Pancreatic Head Resection